How To Deal With High Dose Opioids: Better Storage, Disposal And Advertising
Executive Summary
Beyond considering removal from the market, US FDA advisory panel suggests actions agency could take to improve the safety of higher dosage strength opioids.
You may also be interested in...
Will US FDA Remove Higher Strength Opioids From The Market?
Advisory committee members are divided on whether agency should restrict access to higher dose opioids, but most want option kept on the table.
Opioid Blister Pack Mandate Could Be Phased-In Based On Prescription Volume
US FDA seeks public input on potential advantages and challenges of requiring 5-, 10, and -15-count blister packs for certain opioids and the idea of staggering implementation.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.